Fatima AlKaabi
Affiliated Associate Professor of Personalized Medicine
Research Interests
Professor AlKaabi's research interests include regulatory science, health innovation policy, and the integration of advanced therapeutics with regenerative medicine, precision genomics, and AI-enabled clinical care.
Email
In addition to her position at MBZUAI, Professor AlKaabi is a Director General of Emirates Drug Establishment (EDE), Executive Director of AD-BMT program at Abu Dhabi Stem Cell Center (ADSCC), Vice Chairman of National Multiple Sclerosis Society (NMSS), Chairperson of UAE biotechnology Research Center (UAEBRC) as well as a Consultant hematologist at Yas Clinic Hospital in Abu Dhabi.
-
Master of Science in Cancer, University College of London (UCL), 2012
-
Master's in Public Health, Bloomberg School of Public Health, John Hopkins University, 2011
-
MBBS, Medicine, United Arab Emirates University, Faculty of Medicine & Health Sciences, Al Ain, UAE, 2005
- Hometown Heroine Award (Forbes 30/50)
- Early immune reconstitution assessment by flow/mass cytometry in autologous hematopoietic transplantation performed in a patient with multiple myeloma.
- Recurrent clumping in the extracorporeal photopheresis circuit using acid citrate dextrose solution A.
- Collection efficiency of double- versus single-needle apheresis in mononuclear cell therapy manufacturing.
- Mononuclear cell recruitment during extracorporeal photopheresis: Partial results of a phase 1/2 randomized clinical trial in multiple sclerosis.
- A randomized clinical trial, Abu Dhabi, 2020 – insights into mononuclear cell mobilization in autoimmune diseases.
- Partial results of a phase 1/2 randomized clinical trial in multiple sclerosis – mononuclear cell recruitment during ECP.
- First review of multiple myeloma patients in Sheikh Khalifa Medical City, Abu Dhabi, United Arab Emirates.